Peptide-targeted PEG-liposomes in anti-angiogenic therapy

International Journal of Pharmaceutics

Volumn 254, Issue 1, 2003, Pages 55-58

  Janssen, A P C A ^a   Schiffelers, R M ^a   Ten Hagen, T L M ^b   Koning, G A ^a   Schraa, A J ^c   Kok, R J ^c   Storm, G ^a   Molema, G ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Endothelial cells; Liposomes; RGD peptides

Indexed keywords

ALANYLTHREONYLTRYPTOPHYLLEUCYLPROLYLPROLYLARGININE; ANGIOGENESIS INHIBITOR; ARGINYLALANYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; LIPOSOME; MACROGOL; POLYPEPTIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; DRUG TARGETING; ENDOTHELIUM; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR VASCULARIZATION;

EID: 0037453165     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00682-8     Document Type: Conference Paper

References (8)

1. Binetruy-Tournaire R., Demangel C.et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 19(7):2000;1525-1533.
2. Brooks P.C., Clark R.A.et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264(5158):1994;569-571.
3. Drake C.J., Cheresh D.A.et al. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell Sci. 108(Pt 7):1995;2655-2661.
4. Eliceiri B.P., Cheresh D.A. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103(9):1999;1227-1230.
5. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52(2):2000;237-268.
6. Papenfuss H.D., Gross J.F.et al. A transparent access chamber for the rat dorsal skin fold. Microvasc. Res. 18(3):1979;311-318.
7. Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12:1996;697-715.
8. Vingerhoeds M.H., Haisma H.J. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Pharm. Res. 13(4):1996;604-610.